Interestingly, APRIL can promote immune responses in the tumor microenvironment that are beneficial for its growth while inhibiting responses that could lead to the elimination of tumor cells (especially through interaction with the TACI and BCMA receptors) [5,49]. This evidence concerns the gene TNFSF13 and neoplasm.